Is the business good?
How good a business is CORT?
Corcept Therapeutics Incorporated earns −2.2% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−2.2%
Return on invested capital · cost of capital 9.0% · 11 points below what the capital costs: growth destroys value
- Operating margin
- −1.1%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Cash conversion
- 2.54×
Cash conversion · 1.32× a year ago · every dollar of reported profit arrived as cash, and more
- Share count, year on year
- −13%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2020 | 36% |
| FY2021 | 34% |
| FY2022 | 28% |
| FY2023 | 22% |
| FY2024 | 20% |
| FY2025 | 5.9% |
Details›
- Gross margin12 months to Q1 2026
- 98%
- Operating margin12 months to Q1 2026
- −1.1%
- Net margin12 months to Q1 2026
- 6.2%
- Free cash flow margin
- 16%
- R&D as % of revenue
- 34%
- Revenue, trailing twelve months
- $769M
- Free cash flow, trailing twelve months
- $120M
- Net income, trailing twelve months
- $47M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −2.2%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.